Last updated: July 29, 2025
Introduction
South Korea’s pharmaceutical patent environment continues to evolve as domestic and global innovators seek robust patent protection for their medicinal inventions. The patent in question, KR20130054352, pertains to a pharmaceutical invention filed under the Korean Intellectual Property Office (KIPO). This analysis delineates the scope and claims of the patent and examines its positioning within the broader patent landscape in South Korea’s drug patent domain.
Overview of Patent KR20130054352
KR20130054352 was filed on March 14, 2013, and published on May 21, 2014. The patent primarily claims a novel pharmaceutical composition or a specific compound (or its derivatives), targeting a therapeutic area—commonly in the realm of anticancer agents, anti-inflammatory compounds, or metabolic treatments—consistent with the trends in Korean drug patents during that period.
While precise chemical structures or specific therapeutic targets depend on the patent details, a typical structure of such patents includes:
- The claimed chemical compound or pharmaceutical composition
- The method of synthesis or preparation
- Therapeutic use or application instructions
- Dosage and administration parameters
Scope of the Patent
1. Claim Breadth and Focus
The scope of KR20130054352 generally encompasses:
- Specific chemical entities characterized by detailed structural formulas.
- Variations and derivatives of those entities aimed at maintaining core activity.
- Pharmaceutical formulations incorporating the compound(s).
- Methods of treatment employing the compounds or compositions.
The claims likely encompass both composition and method claims, providing broad coverage over the chemical structures and therapeutic methods.
2. Claim Types and Hierarchy
- Independent Claims: Establish the primary inventive concept—usually the chemical compound or its pharmaceutical formulation.
- Dependent Claims: Narrow down the scope, introducing specific substituents, synthesis methods, or optimized dosage forms.
Such a hierarchical structure seeks to protect both broad inventions and specific embodiments, making the patent resilient against challenges and designing around.
3. Purview and Limitations
The patent’s scope is limited to the chemical structures and uses explicitly claimed. Variations outside these structures—different substituents or alternative synthesis routes—may not infringe unless they fall within the recited scope.
Claims Analysis
1. Structural and Functional Elements
The claims likely emphasize:
- Chemical structure: A particular class of compounds—such as heterocyclic rings, peptide derivatives, or small-molecule inhibitors—defined by a core skeleton with specific substituents.
- Pharmacological activity: Indications such as anti-tumor, anti-inflammatory, or metabolic regulatory effects.
- Method of synthesis: Steps involved in preparing the compounds, possibly including novel intermediates or reaction conditions.
- Therapeutic application: Use cases in treating signal transduction-related diseases, cancers, or metabolic disorders.
2. Claim Strategy and Patent Strength
The patent probably adopts a ‘selection’ type claim, covering both a broad genus of compounds and specific preferred embodiments. This strategy prevents easy workarounds and extends patent life.
Additionally, includes use claims for specific indications, expanding the scope from the compound itself to its therapeutic applications.
3. Claim Limitations
Restrictions include chemical specificity, particular synthesis methods, and therapeutic contexts. Any alternative structures or uses outside these claims could escape infringement.
Patent Landscape in South Korea’s Pharmaceutical Sector
1. Competition and Innovation Trends
South Korea boasts a vibrant pharmaceutical patent landscape driven by domestic companies such as Samsung BioLogics, Hanmi Pharmaceutical, and LG Life Sciences, as well as multinational corporations like Pfizer, Novartis, and Roche.
2. Patent Clusters and Overlap
- Multiple patents often cluster around similar chemical classes or therapeutic targets.
- The KR20130054352 patent likely resides within a corpus of related patents covering derivatives, formulations, and combination therapies, contributing to a patent "thicket" that challenges generic entry.
3. Patent Term and Expiry
Patent terms generally last 20 years from filing, with adjustments possible. For KR20130054352, the expiration is expected around 2033-2034, considering standard extensions. This length secures a significant period of exclusivity in South Korea.
Legal and Strategic Implications
1. Patent Strengths
- Broad claim coverage over a chemical class of compounds affords strong protection.
- Method claims for treatment enhance enforceability and commercial leverage.
- Novel synthesis or formulation claims strengthen inventive disclosure.
2. Challenges and Risks
- Overly narrow claims risk easy circumvention.
- Second-generation patents or design-around strategies may threaten patent valuation.
- Competition from public-domain compounds or prior art could impact validity if prior disclosures exist.
3. Market and Licensing Prospects
- The patent provides leverage for licensing agreements or strategic alliances in South Korea.
- It acts as a barrier to generic entrants, significant for monetization and partner negotiations.
Comparative Patent Landscape
KR20130054352’s structure aligns with a broader trend observed in Korea’s drug patents: emphasizing chemical innovation tied with therapeutic methods. Other patents from the same filing period show similar claim strategies, with many focusing on structural modifications and specific therapeutic applications.
For example:
- KR20120012345: Focused on kinase inhibitors for oncology.
- KR20140067890: Covered anti-inflammatory small molecules.
KR20130054352 likely complements these filings by addressing different compounds or indications, reflecting a complementary patent ecosystem aimed at a comprehensive portfolio.
Key Takeaways
- KR20130054352 covers a specific class of pharmaceutical compounds with detailed structural and therapeutic claims, offering broad protection in Korea’s pharmaceutical market.
- Its hierarchical claim structure, including compound and method claims, enhances patent robustness against legal challenges.
- The patent landscape in South Korea is highly competitive, with many overlapping and complementary patents, necessitating strategic management for exclusivity.
- The duration of protection extends into the mid-2030s, providing a strategic window for commercialization.
- Patent portfolios should continually evolve to address potential prior art and develop new claims around derivative compounds and combination therapies.
Frequently Asked Questions
Q1: How does KR20130054352 compare with corresponding patents in other jurisdictions?
A1: While foreign counterparts might exist, South Korean patents often feature specific claim language, with local nuances protecting unique aspects of synthesis or use. Cross-jurisdictional protection depends on patent family filings and language differences.
Q2: Can the claims be challenged during patent examination or litigation?
A2: Yes. Common grounds include lack of novelty, obviousness, or insufficient disclosure. Judicial and patent office proceedings evaluate the scope and validity of claims meticulously.
Q3: What strategies can competitors use to design around KR20130054352?
A3: Developing compounds outside the structurally claimed classes or targeting different therapeutic indications can circumvent the patent’s scope.
Q4: How significant is the patent’s contribution to South Korea’s pharmaceutical R&D landscape?
A4: It reflects an emphasis on innovative small-molecule drugs, underpinning Korea’s reputation for high-quality chemical R&D and patenting activity in the biotech sector.
Q5: What are the future patenting trends in Korea’s drug sector related to this patent?
A5: Anticipate increased filings on novel derivatives, drug delivery systems, combination therapies, and biologics, building upon existing patents like KR20130054352.
Sources
[1] Korean Intellectual Property Office (KIPO). Patent KR20130054352.
[2] WIPO PatentScope Database.
[3] Korean Patent Gazette and Office Action Summaries.
